Alumis Inc. (ALMS) Price & Analysis

Compare

200 Followers

ALMS Stock Chart & Stats

$5.52

-$0.47(-5.84%)

At close: Jan 08 4:00 PM EST

$5.52

-$0.47(-5.84%)

Day’s Range― - ―

52-Week Range$2.76 - $10.49

Previous CloseN/A

Volume29.29K

Average Volume (3M)772.35K

Market Cap

$574.43M

Enterprise Value$75.47M

Total Cash (Recent Filing)$377.72M

Total Debt (Recent Filing)$37.80M

Price to Earnings (P/E)―

Beta-2.14

Next Earnings

Mar 25, 2026

EPS Estimate

-0.95

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding96,879,395

10 Day Avg. Volume1,046,298

30 Day Avg. Volume772,354

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.86

Price to Sales (P/S)0.00

P/FCF Ratio-0.87

Enterprise Value/Market Cap0.13

Enterprise Value/Revenue3.41

Enterprise Value/Gross Profit3.92

Enterprise Value/Ebitda-0.18

Forecast

1Y Price Target

$19.50

Price Target Upside253.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug ValuationThe market is assigning negligible value to a drug that clearly exceeds Sotyktu’s benchmarks, indicating a potential undervaluation of Alumis.

Financial EfficiencyThe reduction in R&D and SG&A expenses indicates improved financial efficiency, which is expected to fund operations into 2027.

Pipeline GrowthAlumis is not a 'one-asset story'—the pipeline behind envu is active, catalyst-rich, and overlooked, providing potential for future growth.

Bears Say

Trial Advancement RiskRisks include the inability to advance envu into pivotal trials in a timely fashion and failure to secure approval in major markets.

Alumis Inc. News

Alumis reports Q3 revenue $2.07M, consensus $3.14M

“As we continue to advance our pipeline, we are entering an important period for Alumis (ALMS). Our teams...

6d ago

ALMS

Alumis Inc. Advances Pipeline Amid Financial Challenges

Alumis Inc. ( ($ALMS) ) has released its Q3 earnings. Here is a breakdown of the information Alumis...

6d ago

ALMS

ALMS Earnings this Week: How Will it Perform?

Alumis Inc. (ALMS) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

10d ago

ALMS

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer in Psoriasis Treatment

Alumis Inc. (($ALMS)) announced an update on their ongoing clinical study. Study Overview: Alumis Inc. is conducting a...

23d ago

ALMS

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer for Renal Impairment Treatment

Alumis Inc. (($ALMS)) announced an update on their ongoing clinical study. Study Overview: Alumis Inc. is conducting a...

23d ago

ALMS

Alumis Inc.’s ESK-001 Study: A Potential Game-Changer for Hepatic Impairment Treatment?

Alumis Inc. (($ALMS)) announced an update on their ongoing clinical study. Alumis Inc. is conducting a Phase 1...

23d ago

ALMS

Alumis Inc. Updates Corporate Presentation on Pipeline

Alumis Inc. ( ($ALMS) ) has shared an update. On September 3, 2025, Alumis Inc. updated its corporate...

3M ago

ALMS

Alumis Inc. Reports Q2 2025 Earnings and Strategic Advances

Alumis Inc. ( ($ALMS) ) has released its Q2 earnings. Here is a breakdown of the information Alumis...

3M ago

ALMS

ALMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Alumis Inc. (ALMS) is scheduled to report 2nd quarter earnings on 08/19/2025. Regarding Q2 estimates, Wall Street analysts...

3M ago

ALMS

Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic Positioning

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. and keeping the price target...

3M ago

ALMS

Alumis reports Q2 revenue $2.67M, consensus $2.43M

As of June 30, Alumis (ALMS) had cash, cash equivalents and marketable securities of $486.3M. “With patient enrollment...

3M ago

ALMS

Alumis Inc. Concludes 2025 Annual Stockholders Meeting

The latest announcement is out from Alumis Inc. ( ($ALMS) ). On July 30, 2025, Alumis Inc. held...

4M ago

ALMS

Alumis initiated with an Overweight at Wells Fargo

Wells Fargo analyst Derek Archila initiated coverage of Alumis (ALMS) with an Overweight rating and $17 price target...

4M ago

ALMS

Alumis completes patient enrollment in global LUMUS Phase 2b trial of ESK-001

Alumis (ALMS) announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a...

4M ago

ALMS

ALMS FAQ

What was Alumis Inc.’s price range in the past 12 months?

Alumis Inc. lowest stock price was $2.76 and its highest was $10.49 in the past 12 months.

What is Alumis Inc.’s market cap?

Alumis Inc.’s market cap is $574.43M.

When is Alumis Inc.’s upcoming earnings report date?

Alumis Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 125 days.

How were Alumis Inc.’s earnings last quarter?

Alumis Inc. released its earnings results on Nov 13, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$1.036 by -$0.024.

Is Alumis Inc. overvalued?

According to Wall Street analysts Alumis Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alumis Inc. pay dividends?

Alumis Inc. does not currently pay dividends.

What is Alumis Inc.’s EPS estimate?

Alumis Inc.’s EPS estimate is -0.95.

How many shares outstanding does Alumis Inc. have?

Alumis Inc. has 96,879,395 shares outstanding.

What happened to Alumis Inc.’s price movement after its last earnings report?

Alumis Inc. reported an EPS of -$1.06 in its last earnings report, missing expectations of -$1.036. Following the earnings report the stock price went up 4.545%.

Which hedge fund is a major shareholder of Alumis Inc.?

Currently, no hedge funds are holding shares in ALMS

Alumis Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-66.88%

Trailing 12-Months

Asset Growth

18.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alumis Inc.

Alumis Inc. (ALMS) is a biopharmaceutical company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. Leveraging cutting-edge scientific research, Alumis aims to address unmet medical needs by advancing its portfolio of innovative treatments. The company operates primarily in the biotechnology and pharmaceuticals sectors, dedicated to improving patient outcomes through targeted therapeutic solutions.

Alumis Inc. (ALMS) Earnings & Revenues

Historic Earnings Reports

ALMS Stock 12 Month Forecast

Average Price Target

$19.50

▲(253.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.75,6.3076923076923075,7.865384615384615,9.423076923076923,10.98076923076923,12.538461538461538,14.096153846153847,15.653846153846153,17.21153846153846,18.76923076923077,20.326923076923077,21.884615384615383,23.442307692307693,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.75,5.884615384615385,7.019230769230769,8.153846153846153,9.288461538461538,10.423076923076923,11.557692307692307,12.692307692307692,13.826923076923077,14.961538461538462,16.096153846153847,17.23076923076923,18.365384615384613,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.75,5.461538461538462,6.173076923076923,6.884615384615385,7.596153846153847,8.307692307692308,9.01923076923077,9.73076923076923,10.442307692307693,11.153846153846153,11.865384615384617,12.576923076923077,13.288461538461538,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >